GLP-1 for Alzheimer's: A Good Bet That Did Not Pay Out

Novo Nordisk (NVO) closed at $44.56 with a market cap of $195.8 billion. The company spent over $500 million on two Phase 3 trials testing oral semaglutide in Alzheimer’s disease. Both failed. The GLP-1 Alzheimer’s hypothesis is dead as a monotherapy. But the pipeline beyond semaglutide is still alive, and Eli Lilly (LLY), which closed at $1,157.93 with a market cap of $995 billion, is the next company to test it.

The scientific rationale

The logic was elegant. Alzheimer’s disease involves neuroinflammation: activated microglia, elevated cytokines, and progressive synaptic damage. GLP-1 receptors exist on neurons, microglia, and astrocytes. GLP-1 agonists reduce neuroinflammation, improve insulin signaling in the brain, reduce tau phosphorylation, and enhance synaptic plasticity in animal models. This was not a random guess. There was real preclinical biology behind the hypothesis.

The EVOKE trials

Novo Nordisk ran two massive Phase 3 trials. EVOKE enrolled 1,855 patients and EVOKE+ enrolled 1,953 patients across 40 countries, with a 104-week treatment duration. The primary endpoint was change in CDR-Sum of Boxes (CDR-SB) from baseline to Week 104.

The results were unambiguous failures:

• EVOKE: CDR-SB treatment difference of -0.06 points (p=0.77). The drug did nothing on the primary endpoint.
• EVOKE+: CDR-SB difference of 0.15 points (p=0.46). The point estimate actually favored placebo.
• Pooled time-to-dementia hazard ratio: 0.96 (95% CI: 0.86 to 1.06). A 4% reduction that does not clear statistical significance.

The biological activity was real. Semaglutide produced 24-29% reductions in hsCRP, a marker of systemic inflammation. CSF biomarker substudies showed measurable changes in Alzheimer’s-related proteins. The drug was doing something biologically. It just was not doing enough to change the clinical trajectory. For our detailed analysis of the EVOKE failure, see the semaglutide Alzheimer’s failure analysis.

Why it failed

Three hypotheses:

First, neuroinflammation may be a consequence of Alzheimer’s pathology, not a cause. Reducing inflammation after amyloid and tau have already accumulated may be too late. This is the same lesson the anti-amyloid field learned over 20 years of failures.

Second, semaglutide may not cross the blood-brain barrier well enough. GLP-1 receptor density in human brain regions relevant to Alzheimer’s may be too low for peripheral dosing to achieve therapeutic concentrations.

Third, the trial design may have been wrong. The EVOKE trials enrolled patients with early symptomatic Alzheimer’s. By that stage, neurodegeneration may be irreversible regardless of anti-inflammatory intervention.

What is left in the pipeline

Lilly’s tirzepatide (dual GLP-1/GIP agonist) has a Phase 2 Alzheimer’s trial with data expected in 2027. Tirzepatide is a more potent metabolic drug than semaglutide and may have better brain penetration. The rationale is that superior weight loss and metabolic control could translate to greater neuroinflammatory benefit.

Retatrutide (triple GLP-1/GIP/glucagon agonist) is even more potent but earlier in development. Lilly disclosed that the retatrutide Phase 3 program is complete and a BLA filing is planned for Q1 2027 for obesity. An Alzheimer’s program for retatrutide has not been formally announced, but Lilly has both the obesity franchise and the neuroscience infrastructure to explore it.

Combination approaches are the most scientifically interesting. GLP-1 agonists combined with anti-amyloid antibodies (Leqembi, Kisunla) could address both inflammation and plaque pathology simultaneously. No trials are underway, but Lilly owns both tirzepatide and donanemab (Kisunla). For context on why Alzheimer’s trials fail, see our analysis of Alzheimer’s drug development patterns.

Investment implications

For Novo Nordisk at $195.8 billion, the Alzheimer’s failure is immaterial. The GLP-1 franchise (Ozempic, Wegovy) generates over $30 billion in annual revenue. Alzheimer’s was optionality, not the core thesis.

For Lilly at $995 billion, tirzepatide in Alzheimer’s is also optionality. The obesity and diabetes franchise is the engine. An Alzheimer’s approval would be a bonus, not a driver.

For pure-play neuroscience companies, the failure of a well-funded, scientifically rational approach is negative. It reinforces how hard Alzheimer’s drug development is. The 99% failure rate between Phase 2 and Phase 3 for Alzheimer’s drugs now includes GLP-1 agonists. Biogen’s diranersen (anti-tau) is the next neuroscience readout to watch, with Phase 2 CELIA data at AAIC 2026. For that analysis, see our diranersen coverage.

The verdict

The GLP-1 Alzheimer’s hypothesis was a good bet that did not pay out. The science was sound. The execution was solid. The biology did not cooperate. This is the pattern in Alzheimer’s: rational hypotheses fail because the disease is more complex than any single mechanism can address.

The pipeline beyond semaglutide is early and uncertain. Tirzepatide Phase 2 data in 2027 is the next data point. I would not bet on it. I would watch it. The pattern says wait for Phase 2 data before investing in the next Alzheimer’s mechanism.

For GLP-1 sector context more broadly, see our GLP-1 stocks analysis. The obesity franchise is where the money is. Alzheimer’s is where the science is. They are not the same trade.

Source: The Lancet, semaglutide EVOKE trial results